Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass
- Canada’s First Published Psilocybin Trial: Includes Patients with BDII and Personality Disorders, Employs Flexible Repeat Dosing Protocol
- University of Maryland Joins Terran Biosciences’ Complaint Against Compass Pathways
- Further Reading & Other Stories
Canada’s First Published Psilocybin Trial: Includes Patients with BDII and Personality Disorders, Employs Flexible Repeat Dosing Protocol
On Valentine’s Day, Canada’s first randomised trial of psilocybin was published in Med (Rosenblat et al., 2024; NCT05029466). There were plenty of other ‘firsts’, too. The study was the first randomized clinical trial to include those with bipolar II disorder (BDII)1 and the first to adopt a flexible repeat dosing regime, among other things.
It appears that the investigators sought to design this study in a way that better resembles how psilocybin may be used in clinical practice (e.g., repeat doses administered in an “intuitive” manner based on the judgement of a clinician), and the potential patient populations it might be most likely to serve (e.g., patients with complex presentations of depression with comorbidities, who are highly refractory...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks